8.80Open8.80Pre Close0 Volume111 Open Interest12.50Strike Price0.00Turnover0.00%IV7.04%PremiumJan 17, 2025Expiry Date8.52Intrinsic Value100Multiplier6DDays to Expiry0.28Extrinsic Value100Contract SizeAmericanOptions Type--Delta--Gamma0.47Leverage Ratio--Theta--Rho--Eff Leverage--Vega
Biomea Fusion Stock Discussion
Icovamenib, in combination with semaglutide, approximately doubled C-peptide production per unit of glucose compared to semaglutide alone leading to a 60% improved reduction of fasting blood glucose
Ex vivo human islet experiments pr...
Biomea Fusion Reports New Preclinical Data on Icovamenib-Semaglutide Combination Study Thanks @Jaguar8 For spotting since for some reason they say no more posts???
Icovamenib met the primary endpoint, displaying a meaningful statistically significant placebo-corrected mean reduction in HbA1c in the prespecified per protocol patient population
Icovamenib was well-tolerated, with no adverse-event related discontinuations, no hypoglycemic events and no serious adverse events
Yet all the analysts are giving target price from a low 11$ to a 50/60 and above.
What's your take?
No comment yet